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Abstract: (1) Background: Until now, several reports about pregnant women with confirmed coronavirus
disease 2019 (COVID-19) have been published. However, there are no comprehensive systematic reviews
collecting all case series studies on data regarding adverse pregnancy outcomes, especially association
with treatment modalities. (2) Objective: We aimed to synthesize the most up-to-date and relevant
available evidence on the outcomes of pregnant women with laboratory-confirmed infection with
COVID-19. (3) Methods: PubMed, Scopus, MEDLINE, Google scholar, and Embase were explored
for studies and papers regarding pregnant women with COVID-19, including obstetrical, perinatal,
and neonatal outcomes and complications published from 1 January 2020 to 4 May 2020. Systematic review
and search of the published literature was done using the Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA). (4) Results: In total, 11 case series studies comprising 104
pregnant women with COVID-19 were included in our review. Fever (58.6%) and cough (30.7%)
were the most common symptoms. Other symptoms included dyspnea (14.4%), chest discomfort
(3.9%), sputum production (1.0%), sore throat (2.9%), and nasal obstruction (1.0%). Fifty-two patients
(50.0%) eventually demonstrated abnormal chest CT, and of those with ground glass opacity (GGO),
23 (22.1%) were bilateral and 10 (9.6%) were unilateral. The most common treatment for COVID-19 was
administration of antibiotics (25.9%) followed by antivirals (17.3%). Cesarean section was the mode of
delivery for half of the women (50.0%), although no information was available for 28.8% of the cases.
Regarding obstetrical and neonatal outcomes, fetal distress (13.5%), pre-labor rupture of membranes
(9.6%), prematurity (8.7%), fetal death (4.8%), and abortion (2.9%) were reported. There are no positive
results of neonatal infection by RT-PCR. (5) Conclusions: Although we have found that pregnancy with
COVID-19 has significantly higher maternal mortality ratio compared to that of pregnancy without
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the disease, the evidence is too weak to state that COVID-19 results in poorer maternal outcome due
to multiple factors. The number of COVID-19 pregnancy outcomes was not large enough to draw
a conclusion and long-term outcomes are yet to be determined as the pandemic is still unfolding.
Active and intensive follow-up is needed in order to provide robust data for future studies.
Keywords: coronavirus disease 2019; pregnancy; COVID-19; fetal death; neonatal outcomes;
preterm birth; SARS-CoV-2; stillbirth; maternal morbidity; maternal mortality; neonatal morbidity;
neonatal mortality
1. Introduction
In December 2019, outbreaks of respiratory disease caused by a novel severe acute respiratory
syndrome coronavirus (SARS-CoV-2) were reported in China. The disease was officially named
coronavirus disease 19 (COVID-19) by the World Health Organization (WHO) and was declared a
pandemic on 11th March 2020 [1]. Infected patients typically present with fever, cough, or fatigue [2].
Ground glass opacities (GGO) are a commonly seen radiological finding [3]. Reported estimates for
the case fatality rate range from 3% to 15% [4].
Maternal physiological changes during pregnancy predispose pregnant women to infectious
disease. Physiologically, progesterone-mediated vasodilation observed in pregnancy increases mucosal
edema and leads to rhinitis or epistaxis. Lung fluid is also increased, and the diaphragm is elevated
4–5 cm to encompass the growing fetus [5]. During the later stages of pregnancy, the activity of
cluster of differentiation (CD)4+ T cells, CD8+ T cells, B cells, and natural killer cells are reduced,
increasing the pregnant woman’s vulnerability to severe infection [6]. Viral pneumonia is the most
common non-obstetric infection in pregnancy [7] and has been historically associated with increased
morbidity and mortality in pregnant women [6,8]. One-fifth of pregnant women with pneumonia
experience respiratory failure necessitating mechanical ventilation [9]. Furthermore, viral pneumonia
is typically more severe and less responsive to treatment compared to bacterial pneumonia among
pregnant women [7]. Higher estradiol and progesterone concentrations promote the development
of T-helper cell type 2 (Th2) cells, which drive a shift toward humoral, rather than cell-mediated
immunity and further reduce the body’s capability to fight viral incursion [6,10,11]. The developing
fetus is also highly susceptible to infection, hypoxia, and aberrantly increased maternal cytokines or
complement activation associated with infection [12,13]. Pneumonia during pregnancy is associated
with low birthweight, preterm birth, cesarean section, preeclampsia/eclampsia, and Apgar scores <7 at
5 min [14].
Previous studies have shown that infection with severe acute respiratory syndrome coronavirus
(SARS) or Middle East respiratory syndrome (MERS) during pregnancy is linked to adverse outcomes.
For example, increased maternal death, spontaneous abortions, and intensive care unit (ICU) admission
in pregnancies with SARS-CoV have been previously reported [15–17]. In a case series with 11 pregnant
patients with MERS, the case fatality rate was 35% [18]. However, data on the outcome of COVID-19
infection during pregnancy, including prognosis, are scarce. Furthermore, although recent results
show that the isolation associated with COVID-19 control measures is not associated with depressive
mental outcomes in pregnant women, the physiological health outcomes of pregnant patients of
COVID-19 require further study [19]. It is important that the effect of COVID-19 on the health outcomes
of pregnant patients is clearly understood so that healthcare workers can be adequately equipped
with knowledge about the prognoses and management of pregnant women with COVID-19. Thus,
to aggregate growing evidence regarding this topic, we performed a systematic review evaluating
the prognosis and other factors, including clinical characteristics, management, and associated health
outcomes of COVID-19 infection in pregnancy.
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2. Materials and Methods
Literature Search Strategy and Selection Criteria
We performed a comprehensive systematic review and search of the published literature using
the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). PubMed,
Scopus, MEDLINE, Google scholar, and Embase were the databases used to search for evidence
and articles published between 1 January 2020 and 4 May 2020. Only articles in the English language
were included. A combination of “Coronavirus 19”, “COVID-19”, “SARS-CoV-2”, “2019-nCoV”,
“novel coronavirus 2019”, “pregnancy” were the search Medical Subject Headings (MeSH) terms
(Table S2). Manual search and screening of all articles were also carried out. Our inclusion
criteria consisted of all manuscript discussing pregnant women affected with COVID-19 infection,
including obstetrical, perinatal, and neonatal outcomes and complications. All other manuscripts were
excluded. We included case series and retrospective studies, excluding simple case reports.
Two investigators (K.H.L. and M.K.(Moonsu Kwak)) appraised and screened the data
independently. The examiners made sure not to include any overlap or duplicates. Any discrepancy
was resolved via discussion and subsequent consensus. The quality of the studies that satisfied the
inclusion criteria was evaluated using the Newcastle–Ottawa scale by two different investigators
autonomously. The appraisal framework reported by Murad et al. [20] was used to adjust for the
added risk of bias created by case series analysis. The studies were categorized as either of good,
fair, or poor quality. Three hundred twenty one articles were manually reviewed by title screening.
One hundred eighty two articles were excluded because they did not report any data regarding
COVID-19 or COVID-19 in pregnant women. After reviewing 139 articles manually by abstract
screening, 40 manuscripts were further excluded because they did not satisfy our inclusion criteria.
Out of the remaining 99 articles, 88 were excluded after full text screening. Therefore, 11 articles
were eligible for review in our study. A flow-chart of literature search is presented in Figure 1.
Statistical analysis was carried out using SPSS (Version 25, IBM). Continuous variables were reported
as means, and categorical ones as percentages.
Figure 1. Flow chart of literature search.
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3. Results
3.1. Summary of Previously Published Meta-Analyses
Until now, seven meta-analyses on adverse pregnancy outcome of COVID-19 have been identified
(Table 1). Mascio et al. [21] performed a meta-analysis on pregnancy outcomes of patients with
SARS, MERS, and COVID-19. Chest computed tomography (CT) can play an important role
as a viable screening tool for COVID-19 in the pregnant patient even in cases without clinical
symptoms; however, no significant results including chest CT findings and treatment modalities were
described in the manuscript. Four studies—Kasraeian et al. [22], Yang et al. [23], Gatta et al. [24]
and Zaigham et al. [25]—summarized the clinical characteristics of pregnant patients and the overall
outcomes of pregnancy, not describing CT findings and type of treatment. Martar et al. [26] described
overall clinical characteristics, CT findings, and outcomes of pregnancy without type of treatments.
Lastly, Abdollahpour et al. [27] described the previous published papers, but there are no summarized
data of clinical pregnancy outcomes.
Table 1. Main characteristics and findings of the previous published systematic reviews/meta-analyses.
Authors IncludedStudies, n
Sample
Size Study Period Description Comment
Mascio et al.
2020 [21] 19 79
Until 13
March 2020
In mothers infected with
coronavirus infections,
including COVID-19, >90%
of whom also had
pneumonia, preterm birth is




death (7-11%) were also















9 87 Until 18March 2020
Most pregnant patients
suffered from mild or
moderate COVID-19
pneumonia with no
pregnancy loss, proposing a
similar pattern of the clinical
characteristics of COVID-19


















The clinical characteristics of
pregnant women with
COVID-19 are similar to
those of nonpregnant adults.
Fetal and neonatal outcomes
appear good in most cases,
but available data only
include pregnant women
















Size Study Period Description Comment
Gatta et al.
(2020) [24] 6 51
Until 14
March 2020
3 pregnancies were ongoing;
of the remaining 48 pregnant
women, 46 gave birth by
cesarean delivery, and 2
gave birth vaginally; in this


















women presenting in the
third trimester with fever
(68%) and coughing (34%).
Lymphocytopenia (59%)
with elevated CRP (70%)
was observed and 91% of the
women were delivered by
cesarean section. Three
maternal intensive care unit
admissions were noted but
no maternal deaths. One
neonatal death and one






















GGO was the most common
radiological finding (81.7%).
Preterm birth rate was 37.7%
and cesarean delivery rate
was 76%. There was one
maternal death. There were










29 NA Until 25March 2020
In conclusion, improving
quality of care in maternal
health, as well as educating,
training, and supporting
healthcare providers in








N: number, COVID-19: coronavirus disease 19, CT: computed tomography, GGO: ground glass opacities, SARS:
severe acute respiratory syndrome, MERS: Middle East respiratory syndrome, CRP: C-reactive protein, NA:
not mentioned.
3.2. Study Selection and Maternal Characteristics
We identified 321 articles. Ninety-nine articles were reviewed by full text screening, and 11
articles on COVID-19 prognosis in pregnant women were eligible for quantitative analysis. All
11 studies were case series on COVID-19 prognosis in pregnant women. Many articles did not
include discussion or did not focus on maternal prognosis in pregnancy with COVID-19. These 11
articles adequately reported maternal prognoses and were included in the final quantitative analysis
(Supplementary Table S4) [28–38].
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These 11 studies encompassed 104 pregnant women infected with COVID-19. Maternal characteristics
are summarized in Table 2. Sixty-eight percent of women were between the ages of 25 and 34. The median
gestational age (GA) was 37 weeks and 6 days. Ninety-one cases originated from China, and nine cases from
Iran and four cases from Italy. Two pregnancies were dichorionic diamniotic twin pregnancies and were
each counted as one delivery in analyses. COVID-19 was confirmed by reverse-transcriptase polymerase
chain-reaction (RT-PCR) in 72 patients. When RT-PCR was not performed, diagnosis was confirmed by the
presence of symptoms and abnormal radiological findings on CT scans. Clinical characteristics of each case
are reported in Supplementary Table S4.
Table 2. Baseline characteristics of pregnant patients with COVID-19.

















Not done 12 (11.6%)




No information 41 (39.4%)
COVID-19: coronavirus disease-19, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, RT-PCR:
reverse transcription polymerase chain reaction, N: number.
3.3. Maternal Findings and Outcomes
Initial symptoms occurred in 74 patients (71.2%) and are summarized in Table 3. Symptoms most
commonly reported were fever (58.6%), cough (30.7%), and dyspnea (14.4%). Less common were chest
discomfort (3.9%) and sore throat (2.9%). One patient reported nasal congestion, and another single
patient reported excessive sputum production. Forty-seven women reported only one symptom at the
time of admission.
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Table 3. Initial symptoms of pregnant patients with COVID-19.








Sore throat 3 (2.9%)
Nasal obstruction 1 (1.0%)
* Chest discomfort includes chest distress, chest pain, and chest tightness. COVID-19: coronavirus disease-19,
N: number.
Fifty-two patients (50.0%) eventually demonstrated abnormal chest CT, and only one patient
did not present with any abnormal findings (Table 4). Of those with GGO, 23 (22.1%) were bilateral
and 10 (9.6%) were unilateral. When bilateral or unilateral GGOs were not specified, 23 (22.1%) were
positive, and only 1 (1.0%) was negative for GGO.
Table 4. CT findings of pregnant patients with COVID-19.










No information 47 (45.2%)
* GGO positive is indicated when bilateral or unilateral is not specified in the paper. GGO: ground glass opacity,
COVID-19: coronavirus disease-19, CT: computed tomography, N: number.
A majority of women (n = 73, 70.2%) received no treatment (Table 5). Most common
treatments reported were antibiotics (25.9%), antivirals (17.3%), and hydroxychloroquine (9.6%).
Common antibiotics included ceftriaxone, vancomycin, and azithromycin. Common antivirals included
oseltamivir and lopinavir/ritonavir. Twenty women received one or two types of treatment, such as
antibiotics combined with antivirals, and eleven women received three or more types of treatment.
Table 5. Treatment of pregnant patients with COVID-19.






COVID-19: coronavirus disease-19, N: number.
Gestational diabetes mellitus, preeclampsia, pre-labor rupture of membranes (PROM), fetal distress,
abortion, prematurity, pregnancy-induced hypertension, placental abruption, vaginal bleeding,
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and fetal death were reported as obstetrical complications (Table 6). At least one obstetrical complication
was reported in 46 patients. Out of the total cohort of 104 patients, commonly reported obstetrical
complications included fetal distress (13.5%), PROM (9.6%), and prematurity (8.7%). Out of the
30 patients without clinical symptoms for COVID-19, obstetrical complications occurred in 15 cases.
Out of the 104 with presenting symptoms, obstetrical complications occurred in 31 cases. Four of
the five fetal deaths occurred in patients with severe COVID-19 exacerbation and who required ICU
admission prior to delivery.
Table 6. Obstetrical complications of pregnant patients with COVID-19.
Obstetrical Complications Number of Reported Cases/Total Number of Patients (n = 104)
Gestational Diabetes Mellitus 3 (2.9%)
Preeclampsia 6 (5.8%)
PROM 10 (9.6%)
Fetal distress 14 (13.5%)
Abortion 3 (2.9%)
Prematurity 9 (8.7%)
Pregnancy induced HTN 4 (3.8%)
Placental abruption 1 (1.0%)
Vaginal bleeding 1 (1.0%)
Fetal death * 5 (4.8%)
* Fetal death includes stillbirth. COVID-19: coronavirus disease-19, PROM; pre-labor rupture of membranes, HTN;
hypertension, N: number.
Survival data were reported for 63 patients (Table 2). Seven maternal deaths with COVID-19
infection were reported by Hantoushzadeh et al. [38] The seven women reported at least fever, dyspnea,
and cough no more than seven days before admission and died following rapid decompensation to
acute respiratory distress syndrome (ARDS) or septic shock. Five died within ten days of admission,
and the longest survival time after admission was 22 days. Two were 40–49 years old, and the
remaining cases were 25–39. Specifically, patient 1 was admitted with complaints of sore throat and
nasal congestion, in addition to fever, dyspnea, and cough. Twenty-four hours later, she suffered
ARDS and died shortly after following acute hypotension and bradycardia. Patient 2 developed acute
hypoxemia within 2 days of admission and decompensated to ARDS following a cesarean delivery.
Patient 3 decompensated within 36 h of admission and died within the next 3 days while suffering from
persistent hypoxia and end-organ failure. Patient 4 was admitted with pneumonia and tachycardia.
She acutely decompensated 4 days later and died 5 days after admission. Patient 5 was admitted with
pneumonia, which had developed a day after onset of fever and dyspnea. She steadily deteriorated
over 5 days and died. Patient 6 presented with a dichorionic diamniotic twin gestation. A day later,
she acutely decompensated with ARDS, with concern for secondary bacterial pneumonia. She initially
improved but experienced a recurrence of ARDS and died following septic shock, disseminated
intravascular coagulopathy, and left heart failure. It was unknown if she was SARS-CoV-2 positive at
the time of ARDS recurrence. Patient 7 underwent a cesarean delivery due to intermittent hypoxia
on admission day 3, and she was intubated 2 days later. She died 23 days after admission while on
ventilator support.
A comparison of clinical characteristics of the mothers who survived against those who did
not is shown in Table 7. Mothers who suffered severe illness and death were more likely to
present with symptoms at hospitalization, namely, with fever and dyspnea (p = 0.021 and 0.000,
respectively), abnormal CT findings (p = 0.055), and bilateral GGOs (p = 0.020). These mothers were
also receiving more aggressive treatment, with higher rates of antibiotics, antivirals, anticoagulants,
and hydroxychloroquine. Mothers who suffered illness and death were older, though this was below
significance (p = 0.118).
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Table 7. Evaluation of clinical characteristics on maternal outcome.
Variable
Number of Reported Cases (Total n = 104)
Survival or
Unreported (n = 97) Death (n = 7) p Value
Mean age 30 36 0.118
SARS-CoV-2 RT-PCR positive 65 (67.0%) 7 (100%) 0.713
Initial symptoms
Cough 25 (25.8%) 7 (100%) 0.000
Fever 54 (55.7%) 7 (100%) 0.021
Dyspnea 8 (8.2%) 7 (100%) 0.000
Sputum 1 (1.0%) 0 (0%) 0.933
Sore throat 3 (3.1%) 0 (0%) 0.810
Nasal obstruction 1 (1.0%) 0 (0%) 0.933
Abnormal CT findings 45 (46.4%) 7 (100%) 0.055
GGO
Bilateral 17 (17.5%) 6 (85.7%)
0.020
Unilateral 10 (10.3%) 0 (0%)
Positive 23 (23.7%) 0 (0%)
Negative 1 (1.0%) 0 (0%)
Treatment
Antibiotics 20 (20.6%) 7 (100%) 0.000
Antivirals 11 (11.3%) 7 (100%) 0.000
Steroid 3 (3.1%) 0 (0%) 0.810
Anticoagulant 2 (2.1%) 6 (85.7%) 0.000
Hydroxychloroquine 5 (5.2%) 5 (71.4%) 0.000
Delivery method NSVD 21 (21.6%) 1 (14.3%) 0.003C/sec 48 (49.4%) 4 (57.1%)
Obstetrical
complications
Gestational DM 3 (3.1%) 0 (0%) 1.000
Vaginal bleeding 1 (1.0%) 0 (0%) 0.933
Preeclampsia 6 (6.2%) 0 (0%) 1.000
PROM 10 (10.3%) 0 (0%) 0.482
Fetal distress 14 (14.4%) 0 (0%) 0.352
Abortion 3 (3.1%) 0 (0%) 1.000
Prematurity 9 (9.3%) 0 (00%) 0.520
Pregnancy-induced
hypertension 4 (4.1%) 0 (0%) 0.754
Placental abruption 1 (1.0%) 0 (0%) 0.933
Fetal death 1 (1.0%) 4 (57.1%) 0.000
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, RT-PCR: reverse transcription polymerase chain
reaction, CT: computed tomography, GGO: ground glass opacities, NSVD: normal spontaneous vaginal delivery,
C/sec: cesarean section, DM: diabetes mellitus, PROM: prelabor rupture of membranes, N: number.
3.4. Neonatal Findings and Outcomes
In concordance with previous findings, vertical SARS-CoV-2 transmission was not found through
neonatal SARS-CoV-2 RT-PCR because there were no positive results in all neonates who were tested
for SARS-CoV-2 (Table 8). Out of patients with recorded delivery methods, cesarean delivery (52 cases)
was more common than normal spontaneous vaginal delivery (NSVD) (22 cases). Neonatal survival
outcomes were recorded for 63 cases, and 57 were alive by each study’s conclusion.
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Table 8. Characteristics of fetal and neonatal outcomes from COVID-19 pregnancies.
Variable Total Number of Pregnancies (n = 104)
Survival Rate
Alive 57 (54.8%)
Fetal Death 5 (4.8%)
Neonatal Death 1 (1.0%)








Not done 35 (33.6%)
No information 23 (22.2%)
COVID-19: coronavirus disease-19, NSVD: normal spontaneous vaginal delivery, C/sec: cesarean section,
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, RT-PCR: reverse transcription polymerase chain
reaction, N: number.
In the six cases with fetal or neonatal death, most of the mothers suffered from severe COVID-19
and experienced exacerbation of illness as well as hypoxemia prior to fetal death. Four cases of them
were reported by Hantoushzadeh et al. [38] In case 1 (GA 30 + 3 weeks), a stillbirth was delivered by
normal spontaneous vaginal delivery less than 24 h after the mother suffered from ARDS. In case 2
(GA 24 + 0 weeks), the fetal death occurred 72 h after admission, after the mother suffered dyspnea
with acute hypoxemia. Case 3 (GA 24 + 0 weeks) was a twin gestation that suffered intrauterine death
following ARDS, which recurred in the mother 2 weeks after initially stabilizing treatment. Case 4
(GA 36 + 0 weeks) was an intrauterine fetal death upon arrival to labor and delivery, though the mother
did not experience hypoxemia or ARDS before delivery.
Fetal death was precipitated by symptom presentation also observed in adverse maternal outcomes
(Table 9). Fetal deaths were associated with maternal presentation of cough (p = 0.008) and dyspnea
(p = 0.000). Additionally, the mothers were more likely to be treated aggressively with antibiotics,
antivirals, anticoagulants, and hydroxychloroquine.
Table 9. Evaluation of clinical characteristics on fetal outcome.
Variable
Number of Reported Cases (Total n = 104)
Survival or
Unreported (n =100) Death (n = 4)* p Value
Mean age 31 36 0.312
SARS-CoV-2 RT-PCR positive 0 (0.0%) 0 (0.0%) 1.000
Initial symptoms
Cough 28 (28.0%) 4 (100.0%) 0.008
Fever 57 (57.0%) 4 (100.0%) 0.140
Dyspnea 11 (11.0%) 4 (100.0%) 0.000
Sputum 1 (1.0%) 0 (0.0%) 0.962
Sore throat 3 (3.0%) 0 (0.0%) 0.888
Nasal obstruction 1 (1.0%) 0 (0.0%) 0.933
Abnormal CT findings 48 (48.0%) 4 (100.0%) 0.279
GGO
Bilateral 10 (10.0%) 3 (75.0%)
0.301
Unilateral 10 (10.0%) 0 (0.0%)
Positive 23 (23.0%) 0 (0.0%)
Negative 1 (1.0%) 0 (0.0%)
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Table 9. Cont.
Variable
Number of Reported Cases (Total n = 104)
Survival or
Unreported (n =100) Death (n = 4)* p Value
Treatment
Antibiotics 23 (23.0%) 4 (100.0%) 0.004
Antivirals 14 (14.0%) 4 (100.0%) 0.001
Steroid 3 (3.0%) 0 (0.0%) 0.888
Anticoagulant 5 (5.0%) 3 (75.0%) 0.002
Hydroxychloroquine 7 (7.0%) 3 (75.0%) 0.002
Delivery method NSVD 21 (21.0%) 1 (25.0%) 0.001C/sec 51 (51.0%) 1 (25.0%)
Obstetrical
complications
Gestational DM 3 (3.0%) 0 (0.0%) 1.000
Vaginal bleeding 1 (1.0%) 0 (0.0%) 0.962
Preeclampsia 6 (6.0%) 0 (0.0%) 1.000
PROM 10 (10.0%) 0 (0.0%) 0.663
Fetal distress 14 (14.0%) 0 (0.0%) 0.556
Abortion 3 (3.0%) 0 (0.0%) 1.000
Prematurity 9 (8.0%) 0 (0.0%) 0.692
Pregnancy-induced
hypertension 4 (4.0%) 0 (0.0%) 0.853
Placental abruption 1 (1.0%) 0 (0.0%) 0.962
* Fetal death in this table excludes stillbirth. N: number, SARS-CoV-2: severe acute respiratory syndrome coronavirus
2, RT-PCR: reverse transcription polymerase chain reaction, CT: computed tomography, GGO: ground glass opacities,
NSVD: normal spontaneous vaginal delivery, C/sec: cesarean section, DM: diabetes mellitus, PROM: prelabor
rupture of membranes.
4. Discussion
Compared to SARS and MERS, COVID-19 is even more highly infectious. Evaluating the outcomes
and prognosis of COVID-19 during pregnancy is important to control disease severity because adverse
outcomes are associated with SARS and MERS in pregnant women [7,14,18]. Neonatal outcomes,
surgical and anesthesia management, and the possibility of vertical transmission in pregnant women
with COVID-19 have already been reviewed [21–27]. However, to the best of our knowledge, few groups
have evaluated the prognoses of pregnant women infected with COVID-19 [23,27], and none have done
so with the most recent evidence. As COVID-19 is a global threat, it is critical that the knowledge base
is continuously updated with recent evidence. This review summarizes the findings of 104 pregnancies
with COVID-19, with a focus on maternal symptoms, complications, and outcomes, using articles
published until 4 May, 2020. Prognosis of COVID-19 with pregnancy is similar to nonpregnant adults
with COVID-19, but there remains a possible risk in pregnant women for sudden-onset exacerbation of
COVID-19 infection in later trimesters.
Previous systematic reviews have demonstrated that the clinical characteristics of pregnant
women with COVID-19 resemble those of nonpregnant patients with COVID-19 [21–27] (Table 1).
In concordance with these reports, few maternal and neonatal deaths were reported in the 104 patients
examined. Common initial symptoms were fever, dyspnea, and cough. In 30 cases, patients presented
with no clinical symptoms. However, abnormal radiological findings and unilateral or bilateral GGOs
were present in all but one case, even in cases without clinical symptoms, suggesting that chest
CT may remain a viable screening tool for COVID-19 in the pregnant patient. Common obstetrical
complications were PROM, fetal distress, and premature birth, and the presence of clinical symptoms
was not associated with obstetrical complications. Cesarean section was the more prominent delivery
method, though we report a significant proportion of NSVDs (22 out of 74 specified cases). NSVDs were
not associated with poorer outcomes compared to cesarean sections, though indications for cesarean
delivery were largely unspecified. Antibiotics, antivirals, and hydroxychloroquine were the most
frequently used treatments, and 20 of the 31 who were administered treatment received one or two
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types of treatment. As nearly all the mothers and neonates survived, whether certain symptoms,
obstetrical complications, or treatments were associated with better outcomes could not be determined.
Nevertheless, it is important to aggregate these findings to further our understanding of COVID-19
in pregnancy. Particularly concerning treatments, this study aggregates the current treatments for
pregnant patients with COVID-19 across multiple treatment centers alongside neonatal outcomes and
obstetric complications, which may contribute to further studies.
There was little evidence of vertical transmission of SARS-CoV-2. Out of the present 46 cases
in which neonatal RT-PCR results were provided, none showed positive results. In separate studies,
Yang et al. reported that two neonates out of 84 live births tested positive by RT-PCR at 36 hours
and 3 days of age but also stated that postnatal infection was possible [27]. Wang et al. also reported
a case of positive RT-PCR findings in one neonate out of 75, at 36 hours of age that had no contact
with the mother after birth [23]. Coupled with some findings of lymphocytopenia, thrombocytopenia,
and radiological abnormalities in neonates born to mothers with COVID-19, vertical transmission
cannot be ruled out [23].
In all of the cases with maternal death, women decompensated rapidly 1–2 weeks following
initial onset of fever, dyspnea, cough, and abnormal radiological findings. This is also concerning for
neonatal outcomes, as all but one of the neonatal deaths occurred after maternal progression to ARDS
or decompensation. All of the women were within the second to third trimester. The available evidence
does not show if any clinical symptoms or radiological findings were predictive of the rapid deterioration
in these cases, and it cannot be determined whether later stages of pregnancy are associated with
worse outcomes. However, as with nonpregnant adult patients, sudden respiratory decompensation
leading to severe disease can occur in pregnant patients [39]. Recently, New York–Presbyterian Allen
Hospital and Columbia University Irving Medical Center screened a total of 215 pregnant women
delivered infants and identified that most of the patients with confirmed COVID-19 at delivery were
asymptomatic and more than one of eight asymptomatic women who were admitted to the delivery
room unit were positive for SARS-CoV-2 [40]. Additional future studies not only focusing on the
presenting symptoms, laboratory findings, and radiological findings but also asymptomatic pregnant
women associated with COVID-19 are warranted and necessary. Furthermore, the possibility of
exacerbation of COVID-19 infection during later stages of pregnancy should be further evaluated.
Notably, the degree of symptom presentation at the time of hospitalization was associated with
both maternal and neonatal death. Specifically, a higher proportion of women presenting with dyspnea
and cough proceeded to suffer severe illness and subsequent maternal and neonatal death. In mothers,
bilateral GGOs were also predictive of adverse outcome. Subsequently, women with worse outcomes
were administered more intensive treatment. As the mortality cases from Hantoushzadeh et al. all
decompensated quickly to ARDS and death, it is of high importance to further evaluate symptoms at
hospitalization, particularly cough and dyspnea, as predictors of decompensation [38].
The key limitations of the present review are that the studies evaluated often included small sample
sizes, were largely limited to cases in a single country, and had missing case data. To accommodate
for missing data in statistical analyses, we grouped missing data and results associated with survival
(e.g., maternal or neonatal survival) on the assumption that authors were less likely to report on
healthy and uneventful pregnancies. Although this may cause some associating factors of maternal
and neonatal death to be missed, we found that this approach was more conservative in identifying
factors involved in adverse outcome, as only major associations with maternal and neonatal death were
distinguished. Second, in some patients, SARS-CoV-2 was diagnosed by clinical and radiological signs
without laboratory confirmation. Third, all of the reports of maternal death originated from a single
case series, limiting an unbiased perspective of maternal outcomes. We caution against immediate
conclusions as a result but nevertheless urge the further pursuit of evaluating presenting symptoms as
risk factors for severe maternal COVID-19 outcome.
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5. Conclusions
This review has comprehensively and judiciously pooled data and combined the latest evidence
concerning COVID-19 and pregnancy, a rapidly evolving situation. Pregnant women are vulnerable to
pneumonia and other severe coronavirus infections. Although we have found that pregnancy with
COVID-19 has significantly higher maternal mortality ratio compared to that of pregnancy without the
disease, the evidence is too weak to state that COVID-19 results in poorer maternal mortality ratio
due to multiple factors, including the number of COVID-19 pregnancy outcomes we accumulated
being not large enough to draw a conclusion. Long-term outcomes are yet to be determined as the
pandemic is still unfolding. Active and intensive follow-up is needed in order to provide robust data
for future studies.
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